Treatment outcomes of retreated patients with isoniazid/rifampicin resistant pulmonary tuberculosis

Treatment outcomes of retreated patients with isoniazid/rifampicin resistant pulmonary tuberculosis

Abstract Background About 8% of TB cases worldwide are estimated to have rifampicin-susceptible, isoniazid-resistant tuberculosis (Hr-TB), ranging from 5 to 11% regions. However, Hr-TB has not received much attention while comparing to be given high priority to the management of rifampicin-resistant...

Full description

Bibliographic Details
Main Authors: Lijie Zhang, Xiqin Han, Qiping Ge, Wei Shu, Yuxian Sun, Jingtao Gao, Shiheng Xie, Jingping Wang, Weiwei Gao
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Infectious Diseases
Subjects:
Pulmonary tuberculosis
Retreated tuberculosis
Isoniazid resistance
Rifampicin resistance
Treatment outcome
Online Access:https://doi.org/10.1186/s12879-023-08909-2

Internet

https://doi.org/10.1186/s12879-023-08909-2

Similar Items